ヒドロゲノソームを標的とした薬剤開発の可能性
Hydrogenosomes are organelles present in non-mitochondrial organisms such as Trichomonas, where they serve as the site of molecular hydrogen production. While sharing several features with mitochondria—including ATP synthesis, pyruvate metabolism, calcium incorporation, post-translational protein import, and cardiolipin content—hydrogenosomes differ fundamentally by lacking a respiratory chain, cytochromes, F0-F1 ATPase, the tricarboxylic acid cycle, and oxidative phosphorylation. These metabolic distinctions make hydrogenosomes an attractive selective drug target, as agents directed against them are unlikely to harm host-cell mitochondria. Studies with metronidazole and other compounds including beta-Lapachone, colchicine, Taxol, and nocodazole revealed morphological abnormalities in hydrogenosomes, flagella internalization, nucleoid-like electron-dense deposits, and extensive autophagy involving lysosomal degradation of the organelles.
Hydrogenosomes lack the respiratory chain, TCA cycle, and oxidative phosphorylation present in mitochondria, instead producing molecular hydrogen via a distinct metabolic pathway. This biochemical divergence allows selective pharmacological targeting without affecting host-cell mitochondrial function.
The delivery route is not clearly identifiable from this paper. For hydrogen intake, inhalation is the most efficient route; inhalation, however, carries explosion risk (empirical LFL of 10%; high-concentration devices are not recommended).
See also:
https://h2-papers.org/en/papers/18473836